free性video西欧极品,伊人依成久久人综合网,中文字幕人妻一区二区三区熟女,男女高潮激烈无遮挡免费观软件 ,成人3d动漫一区二区三区

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Zydus Cadila gets tentative US FDA approval for Carbidopa and Levodopa extended-release capsules

expresspharmaAugust 03, 2020

Tag: Zydus Cadila , FDA , carbidopa , levodopa , Parkinson

Zydus Cadila has received tentative approval from the USFDA to market Carbidopa and Levodopa Extended-Release Capsules in the strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg.

This medication is used to treat the symptoms of Parkinson’s disease (such as shakiness, stiffness, difficulty moving) or Parkinson-like conditions. The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.

The group now has 295 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.


Previous:Sanofi, GSK to supply 100 mn doses of COVID-19 vaccine to US, in talks with EU for 300 mn doses

Next:GAVI’s new drive for COVID-19 vaccine access in LMIC countries includes India

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service